Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease.

Lipoprotein (Lp) cholesterol and apolipoproteins (apo) A-I and B levels have been shown to be better markers for the presence of coronary artery disease than total cholesterol. In this study, we determined the plasma levels of lipoprotein particles containing apo A-I only (LpA-I), apo A-I and A-II (LpA-I:A-II), apo B and C-III (LpB:C-III) and apo B and E (LpB:E) in 145 patients with coronary artery disease (mean age +/- SD, 51 +/- 7 years) and 135 healthy control men (mean age 49 +/- 11 years). Patients with CAD had lower high density lipoprotein (HDL) cholesterol and apo A-I levels and higher triglycerides and apo had lower high density lipoprotein (HDL) cholesterol and apo A-I levels and higher triglycerides and apo B levels than controls. In patients with CAD, LpA-I (0.341 +/- 0.093 vs. 0.461 +/- 148 g/l) and LpA-I:A-II (0.694 +/- 0.171 vs. 0.899 +/- 0.148 g/l) were lower, whereas LpB:E (0.372 +/- 0.204 vs. 0.235 +/- 0.184 g/l) were higher than in controls (cases vs. controls, all P less than 0.005). No significant differences were observed for LpB:C-III (0.098 +/- 0.057 vs. 0.107 +/- 0.061 g/l, p = 0.235) particles. Discriminant analysis indicates that LpA-II:A-I, LpE:B, LpA-I, and triglycerides best differentiate between cases and controls. Plasma apo C-III (0.027 +/- 0.008 vs. 0.036 +/- 0.020 g/l) and E (0.040 +/- 0.015 vs. 0.055 +/- 0.029 g/l) were lower in the CAD group (P less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  M. Brown,et al.  Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[2]  I. Goldberg,et al.  Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. , 1990, The Journal of biological chemistry.

[3]  Daniel Steinberg,et al.  Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. , 1988, Archives of internal medicine.

[4]  D. Levy,et al.  Cholesterol and mortality. 30 years of follow-up from the Framingham study. , 1987, JAMA.

[5]  J. Fruchart,et al.  Quantification of two different types of apolipoprotein A-I containing lipoprotein particles in plasma by enzyme-linked differential-antibody immunosorbent assay. , 1987, Clinical chemistry.

[6]  A. Zinsmeister,et al.  Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. , 1983, The New England journal of medicine.

[7]  J. Bard,et al.  Profiles of apolipoproteins and apolipoprotein B-containing lipoprotein particles in dyslipoproteinemias. , 1988, Clinical chemistry.

[8]  J. Ordovás,et al.  Metabolism of apolipoproteins A-I, A-II, and A-IV. , 1986, Methods in enzymology.

[9]  S B Hulley,et al.  Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. , 1986, American heart journal.

[10]  J. Fruchart,et al.  Apolipoprotein A-I containing lipoproteins in coronary artery disease. , 1987, Atherosclerosis.

[11]  P. Wilson,et al.  High Density Lipoprotein Cholesterol, Total Cholesterol Screening, and Myocardial Infarction: The Framingham Study , 1988, Arteriosclerosis.

[12]  W. Castelli,et al.  The triglyceride issue: a view from Framingham. , 1986, American heart journal.

[13]  J. Albers,et al.  Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. , 1982, Clinical chemistry.

[14]  J. Fruchart,et al.  Quantitative determination of different apolipoprotein B containing lipoproteins by an enzyme linked immunosorbent assay: apo B with apo C-III and apo B with apo E. , 1991, Journal of immunoassay.

[15]  C. Packard,et al.  Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. , 1984, The Journal of clinical investigation.

[16]  S. Shapiro,et al.  Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. Sniderman,et al.  Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. , 1982, Annals of internal medicine.

[18]  E. Schaefer,et al.  Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. , 1987, Clinica chimica acta; international journal of clinical chemistry.

[19]  P. Wilson,et al.  Enzyme-linked Immunosorbent Assay for Human Plasma Apolipoprotein B , 2022 .

[20]  A. Kissebah,et al.  Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. , 1981, Metabolism: clinical and experimental.

[21]  P. McGrath,et al.  Does intervention by a nurse improve medication compliance? , 1978, Archives of internal medicine.

[22]  R. Norum,et al.  Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. , 1986, The Journal of clinical investigation.

[23]  D R Jacobs,et al.  High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. , 1990, American journal of epidemiology.

[24]  G. Miller,et al.  PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.

[25]  J. Fruchart,et al.  Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. , 1990, Clinical chemistry.

[26]  R. Havel,et al.  Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in normal and lipoprotein lipase-deficient humans. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[27]  V. Clavey,et al.  Quantification of human apolipoprotein E in plasma and lipoprotein subfractions by a non-competitive enzyme immunoassay. , 1987, Clinica chimica acta; international journal of clinical chemistry.

[28]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[29]  J. Fruchart,et al.  Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E. , 1990, Atherosclerosis.

[30]  N. Le,et al.  Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. , 1988, Journal of lipid research.